Ladenburg Thalmann Financial Services’s Sinovac Biotech, Ltd SVA Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	4	–	–	﹤0.01%	5740
2019 Q3	$0	Hold	4	–	–	﹤0.01%	5688
2019 Q2	$0	Buy	+4	New	–	﹤0.01%	5628
2018 Q1	–	Sell	-300	Closed	-$2K	–	5394
2017 Q4	$2K	Hold	300	–	–	﹤0.01%	4863
2017 Q3	$2K	Hold	300	–	–	﹤0.01%	4752
2017 Q2	$2K	Hold	300	–	–	﹤0.01%	4688
2017 Q1	$2K	Hold	300	–	–	﹤0.01%	4663
2016 Q4	$2K	Hold	300	–	–	﹤0.01%	4614
2016 Q3	$2K	Sell	300 -87	-22%	-$512	﹤0.01%	4579
2016 Q2	$3K	Hold	387	–	–	﹤0.01%	4363
2016 Q1	$3K	Sell	387 -3,513	-90%	-$21.1K	﹤0.01%	4341
2015 Q4	$23K	Hold	3,900	–	–	﹤0.01%	3139
2015 Q3	$20K	Buy	3,900 +3,600	+1,200%	+$19.1K	﹤0.01%	3129
2015 Q2	$2K	Hold	300	–	–	﹤0.01%	4441
2015 Q1	$1K	Hold	300	–	–	﹤0.01%	4555
2014 Q4	$2K	Buy	+300	New	+$1.53K	﹤0.01%	4155

Other funds holding SVA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return

Ladenburg Thalmann Financial Services's SVA Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Sinovac Biotech, Ltd (SVA) position steady in Q4 2019 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5740.

Ladenburg Thalmann Financial Services first reported a position in SVA in Q4 2014 and has held it in 16 quarters since. The position peaked at $23K in Q4 2015. 25 funds tracked by Wall St. Rank hold SVA as of Q4 2019.

Ladenburg Thalmann Financial Services held 4 shares of Sinovac Biotech, Ltd worth $0 as of Q4 2019.
Ladenburg Thalmann Financial Services left its Sinovac Biotech, Ltd share count unchanged in Q4 2019.
Sinovac Biotech, Ltd made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5740 holding.
Ladenburg Thalmann Financial Services first reported a position in Sinovac Biotech, Ltd in Q4 2014 and has held it in 16 quarters since.
Ladenburg Thalmann Financial Services's Sinovac Biotech, Ltd position peaked at $23K in Q4 2015.
25 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.